Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder
Authors:
- 18 September 2018
- journal article
- research article
- Published by Impact Journals, LLC in Aging
- Vol. 10 (9) , 2394-2406
Abstract
Rolipram is a selective phosphodiesterase 4 (PDE4) inhibitor that exerts a variety of effects, including anti-inflammatory, immunosuppressive, and anti-tumor effects. The aim of this study was to investigate the effect of rolipram on metabolic disorder and its underlying mechanisms. Metabolic disorder was induced in 8-week-old wild type BABL/c mice by administration of D-galactose for 4 weeks. Simultaneously the mice were administered vehicle or rolipram. Alternatively, beginning at 3 or 21 months, the mice were administered db-cAMP for 3 months, with or without a high-fat-diet (HFD) to induce metabolic disorder. In both models, better metabolic function was observed in rolipram-treated mice. Rolipram reduced adipose deposition and inflammation and reserved metabolic disorder. Treatment with rolipram increased the AMPK phosphorylation and SIRT6 levels in the liver and kidney while reducing NF-κB acetylation. In vitro, these effects were blocked by suppression of SIRT6 expression using specific siRNA. Increased cAMP levels reduced excessive adipose deposition, and improved adipose distribution in presenile mice. These findings provide a promising strategy for the treatment of aging-related metabolic dysfunctions and suggest that selective PDE4 inhibitors may be useful agents for the treatment of aging-related metabolic diseases.Keywords
This publication has 40 references indexed in Scilit:
- Attenuation ofTNFproduction and experimentally induced inflammation byPDE4 inhibitor rolipram is mediated byMAPKphosphatase‐1British Journal of Pharmacology, 2013
- High-Fat Diet Triggers Inflammation-Induced Cleavage of SIRT1 in Adipose Tissue To Promote Metabolic DysfunctionCell Metabolism, 2012
- The sirtuin SIRT6 regulates lifespan in male miceNature, 2012
- Predicting the emetic liability of novel chemical entities: a comparative studyBritish Journal of Pharmacology, 2012
- Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP PhosphodiesterasesCell, 2012
- AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activityNature, 2009
- SIRT6 Links Histone H3 Lysine 9 Deacetylation to NF-κB-Dependent Gene Expression and Organismal Life SpanCell, 2009
- Genomic Instability and Aging-like Phenotype in the Absence of Mammalian SIRT6Cell, 2006
- The Ca2+/Calmodulin-dependent Protein Kinase Kinases Are AMP-activated Protein Kinase KinasesJournal of Biological Chemistry, 2005
- Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinaseCell Metabolism, 2005